When evaluating the severity of this condition, researchers and clinicians increasingly use the lens of oncology to understand its impact. This is not a claim of biological equivalence, but a useful analogy for conveying the disease’s clinical recalcitrance, mortality risk, recurrence burden, and need for coordinated multidisciplinary care.

The Significant Impact on Patients

For patients, a PJI diagnosis can be associated with a decline in their quality of life. The physical impact is significant. Patients often present with severe pain, wound complications and loss of function and reduced mobility.¹ Some individuals undergo multiple revision operations, facing prolonged periods of immobility that limit their independence.¹

The psychological impact can be equally severe. Studies showed that PJI patients often score significantly lower on quality of life metrics than population norms, and in some studies, lower than patients with active cancer, congestive heart failure or stroke.¹ More than 70% of patients with PJI score above the threshold for anxiety and depression.¹ The insidious onset of symptoms creates uncertainty and fear.¹ Some patients even report suicidal thoughts as they struggle with the prolonged treatment pathway.¹

Furthermore, patients often experience a profound 'fear of recurrence'. Similar to cancer survivors waiting for scan results, PJI patients can become hyper-vigilant about every sensation in their joint. The socioeconomic burden is also significant. Many patients, experience major disruption to employment and daily life. Research showed that about 33% of previously working patients under 65 return to work after revision surgery for PJI.

The Emotional Toll on Healthcare Profressionals

The consequences of PJI is not limited to patients. HCPs bear a heavy emotional and psychological burden when managing these complex cases. Dealing with a PJI diagnosis is often described by surgeons as 'devastating' and 'soul-destroying'.

Although PJI is rarely attributable to a single modifiable act or omission, many surgeons still experience a strong sense of personal responsibility because of the profound consequences for the patient. The consequences for the patient are so significant that surgeons often recall these cases years later, remembering patients by name, X-ray appearance and the infecting organism. For some, avoiding infection becomes a primary source of anxiety and clinical focus.

This burden compounded by professional scrutiny. Individual clinical performance outcomes are closely monitored by national registries, hospital boards and colleagues. This creates a skewed sense of accountability and adds moral distress, as surgeons must navigate the delicate balance of taking necessary surgical risks to alleviate patient suffering.

Hospital Operations and Economic Burden

PJI places an immense strain on hospital infrastructure and healthcare systems. Operationally, these cases lead to increased bed occupancy, which in turn causes delays for elective procedures.

The economic burden is substantial. Treating a PJI is estimated to cost between 5.6x more than a primary joint replacement. Despite these high costs, hospital reimbursement models for PJI are often inadequate. Consequently, hospitals frequently lose money on PJI cases.

As the incidence of joint replacements and subsequent infections rises, this financial model becomes increasingly unsustainable for healthcare systems.

A Framework for Understanding: The Cancer Analogy

To grasp the full complexity of PJI, we can look to the conceptual and clinical analogies it shares with malignant disease. Again, these are not claims of literal biological equivalence, but they highlight the clinical recalcitrance of the condition.

Like cancer, PJI carries a significant mortality risk. Recent studies indicated that the five-year mortality rate for PJI following a total hip replacement can reach up to 16%, with ten-year mortality rates reported at 35%. Furthermore, patients with a history of joint infection face a substantially higher risk of recurrence, even in different joints, highlighting a systemic susceptibility or a 'microbial metastasis' that mirrors the systemic nature of cancer.

Biologically, infections often rely on biofilms. Recent microbiological research suggests that biofilms are a multicellular tissue that function similarly to solid tumours.

Even diagnostic challenges are similar. The phenomenon of culture-negative PJI, which happens in up to 30% of cases, represents a diagnostic failure where the infection is present but invisible to standard tests, much like an undetected tumour.

Advancing the Standard of Care

Recognising the deep impact of PJI on all stakeholders is the first step in improving our approach. By understanding the physical, emotional and financial toll of the disease, orthopaedic surgeons and healthcare leaders can work together to build better support systems, refine surgical processes and advocate for fairer reimbursement models.

Key Takeaways

• Recognise the significant emotional impact PJI has on patients, clinical teams and wider support staff, and work collaboratively to develop suitable support structures across the care pathway

• Use validated staging systems such as PJI-TNM to help guide consistent, precision-focused care and shape hospital and system-level protocols

• Promote the formation of multidisciplinary teams to enable coordinated management of complex infections across departments, hospitals and with trusted Medical Technology partners

• Foster a culture of ongoing evaluation and process improvement in both clinical and operational settings, ensuring risks are continually minimised and outcomes enhanced for everyone involved